Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 vs Taxol in Metastatic Breast Cancer
NCT00046527Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2001
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel in breast cancer (2 arms), sponsored by Celgene Corporation. Primary endpoint: Objective Response Rate. Started Jun 2001; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00046527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046527.